FAA Office of Aerospace Medicine Launches MedGuide Tool Listing Approved Medications for Pilots and Air Traffic Controllers

The FAA's Office of Aerospace Medicine this month introduced an online tool called MedGuide, which tells pilots and Air Traffic Control Specialists (ATCS) which medications are considered acceptable while performing flight or safety-related duties. The agency says the tool is not a substitute for medical diagnosis or treatment and should not be used as the sole basis for aeromedical determinations, which must include an individualized assessment. It serves as a reference for airman medical certification and ATCS clearance.

Version 1.0 contains only approved medications; future versions will add conditional and unacceptable medications. Users can select generic, brand-name or over-the-counter drugs from a drop-down menu or type them in. The page then returns FAA frequency limits, typically as prescribed on the label, and wait times based on the user's role. For most drugs this includes an initial wait time, the observation period required after starting a new medication before returning to safety-related duties, typically 48 hours but longer or shorter depending on the drug.

Mark Larsen, director of safety and flight operations at the National Business Aviation Association (NBAA), said the tool, while still a work in progress, equips aviators to make safe, fit-for-flight decisions about medication use.

NBAA is among the organizations backing the Aviation Medication Transparency Act (AMTA) of 2026, which would require the FAA to create a comprehensive list of medications safe for pilots, ATCS and trainees and to indicate how long certificate holders must have limited or no duties while taking certain medications. The Senate passed the AMTA in September and it awaits House approval. Larsen said MedGuide is a big step in the right direction.

The Aircraft Owners and Pilots Association (AOPA) maintains a list of medications appropriate for general aviation pilots, but the FAA has had no such index until now.

NBAA and other groups also support the John A. Hauser Mental Health in Aviation Act, which the Senate also passed in September. It would reduce barriers to seeking mental health treatment, accelerate the FAA's medical approval process, increase funding for the Office of Aerospace Medicine and implement other recommendations of the FAA's Mental Health and Aviation Medical Clearances Aviation Rulemaking Committee. The bill is named after Hauser, a University of North Dakota student who died by suicide in a 2021 airplane crash while training to become a commercial pilot.

Medication questions are a routine friction point in airman medical certification, and until now the closest thing to a reference for general aviation pilots was a list kept by an owners' association rather than by the regulator. An agency-hosted tool changes who holds the baseline: the answer to "is this drug acceptable, and how long must I wait" now comes from the body that issues the certificate, expressed in role-specific wait times and frequency limits. For flight departments and operators with safety-sensitive staff, that gives a common vocabulary for conversations between crew, medical examiners and management.

The tool's present scope is narrow by design. With only approved medications listed, a drug's absence tells a user nothing about whether it is conditional or unacceptable, and the FAA's own caveat that determinations still require an individualized assessment keeps the aviation medical examiner at the center of the process. The tool informs the conversation; it does not settle it.

The next milestones are the addition of conditional and unacceptable medications in later versions, and House action on the Aviation Medication Transparency Act, which would turn a voluntary agency product into a statutory requirement with defined duty limitations.